RYVU THERAPEUTICS ZY-,40/ PLSELVT00013 /
| 10/09/2024 08:27:23 | Chg. +0.1200 | Volume | Bid17:30:01 | Ask17:30:01 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 11.8600EUR | +1.02% | 0 Turnover: 0.0000 |
11.8600Bid Size: 60 | 13.0800Ask Size: 60 | 288.78 mill.EUR | - | - |
GlobeNewswire
11/12/2023
Ryvu Therapeutics Presents Data on RVU120 at the 2023 American Society of Hematology (ASH) Annual Me...
GlobeNewswire
07/12/2023
Ryvu Therapeutics Presents Data on RVU120 at the San Antonio Breast Cancer Symposium 2023
GlobeNewswire
29/11/2023
Ryvu Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
23/10/2023
Ryvu Therapeutics Provides an Update on the Progress of RVU120 Phase I Studies in Patients with Soli...
GlobeNewswire
04/10/2023
Ryvu Therapeutics to Present Preclinical Data on PRMT5 and its Synthetic Lethality Platform at the 2...
GlobeNewswire
13/09/2023
Ryvu Therapeutics Reports 2023 Half-Year Financial Results and Provides Corporate Update
GlobeNewswire
25/06/2021
Roth Capital Partners to Host a Virtual Healthcare Private Company Forum on June 28, 2021
